RHIZEN-PHARMACEUTICALS
Rhizen Pharmaceuticals, a clinical-stage oncology-focussed biopharmaceutical company, today announced the approval of its Investigational New Drug (IND) application by the U.S. Food and Drug Administration (FDA) to study its oral DHODH inhibitor for SARS-CoV-2 infection. The company announced that initial study shall evaluate single ascending doses of RP7214 in healthy volunteers and that dosing is expected to commence in early December 2020. The company also announces positive feedback from the FDA during its pre-IND discussion on its plans to follow-up this study with a multiple-ascending dose study in Covid-19 patients.
Dihydroorotate dehydrogenase (DHOHD) is a key enzyme involved in pyrimidine biosynthesis in the cell. RP7214 is potentially a best-in-class selective DHODH inhibitor that has shown potent inhibition of Covid-19 viral replication. RP7214 has also been studied extensively across multiple inflammation models where it has demonstrated excellent anti-inflammatory activity. Further, the IND-enabling preclinical studies have shown RP7214 to be orally available, safe and tolerable with predictable dose-linear pharmacokinetics. The host-based mechanism of RP7214 could allow complementary combinations with direct acting anti-viral drugs, while the broad anti-inflammatory action could potentially mitigate the cytokine mediated inflammatory symptoms typically seen in SARS-CoV-2 & other viral infections.
Swaroop Vakkalanka, President & CEO of Rhizen Pharmaceuticals said “There is an exceptional need for oral antiviral drugs that are suitable for Covid-19 treatment across all hospital and out-patient settings. We are pleased to advance RP7214 into a Phase 1 clinical trial for the treatment of Covid-19 under a US FDA IND. RP7214 has a unique preclinical profile, high oral bioavailability, robust anti-viral potency and broad anti-inflammatory role, that we expect will translate in the clinic and support its eventual development as a potential treatment for Covid-19 ”.
About Rhizen Pharmaceuticals S.A.:
Rhizen Pharmaceuticals is an innovative, clinical-stage biopharmaceutical company focused on the discovery and development of novel onco-therapeutics. Since its establishment in 2008, Rhizen has created a diverse pipeline of proprietary drug candidates targeting several cancers and immune associated cellular pathways. Rhizen is headquartered in La-Chaux-de-Fonds, Switzerland. For additional information, please visit www.rhizen.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20201201005815/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
KAYTUS Completes 100-Cabinet Liquid-Cooled Data Center in Europe in Four Months6.1.2026 09:02:00 CET | Press release
KAYTUS turnkey modular solution delivered with onsite professional services, improved high-density liquid cooling cluster performance by 20%, and deployment efficiency by 80%. KAYTUS announced that it has accelerated the deployment of large-scale liquid-cooled AI data centers through its integrated turnkey service. By combining deployment and commissioning, KAYTUS delivers a one-stop, end-to-end service, from installation to optimization and launch. Recently, KAYTUS completed the delivery of a 100-cabinet, high-density liquid-cooled AI data center in Europe in just four months, up to 80% faster than traditional deployment models. Through professional performance testing and tuning, overall system performance was improved by 20%, enabling a stable, high-efficiency business launch through on-site optimization and customization. This accelerated and resilient delivery addresses urgent AI infrastructure timelines and provides a scalable blueprint for deploying high-density liquid-cooled cl
Kashiv BioSciences to Present at the 44th Annual J.P. Morgan Healthcare Conference6.1.2026 09:00:00 CET | Press release
Kashiv BioSciences, LLC (“Kashiv”), a vertically integrated biopharmaceutical company, today announced that Dr. Sandeep Athalye, Global Chief Executive Officer, and Dr. Paras Vasanani, Head of Business Development, will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, California, on Wednesday, January 14, 2026, at 11:00 a.m. PST. 44th Annual J.P. Morgan Healthcare Conference – Kashiv BioSciences Company Presentation Date: Wednesday, January 14, 2026 Time: 11:00 - 11:25 a.m. PST Location: Golden Gate Conference Room – The Westin St. Francis Hotel, San Francisco, California About Kashiv BioSciences: Kashiv BioSciences, LLC is a vertically integrated biopharmaceutical company with numerous commercial and advanced clinical-stage assets and is among the few U.S.-based companies to both manufacture and receive marketing authorization for multiple biosimilars. Kashiv BioSciences, LLC in the USA, and its subsidiaries in India (together “Kashiv BioSciences”) operat
CES 2026: GIGABYTE is “AI Forward,” Showcasing AI Factory, Physical AI, and Agentic AI Solutions6.1.2026 01:00:00 CET | Press release
GIGABYTE Technology, a global leader known for its engineering excellence in high-performance computing and AI servers, continues to strengthen its position as one of Taiwan’s most AI-centric server innovators. At CES 2026, GIGABYTE is to present its complete computing ecosystem under the theme “AI Forward”—highlighting how its technologies form the computational backbone of next-generation AI infrastructure, supporting AI development across cloud, edge, and personal devices, and full-stack solutions enabling organizations to deploy AI with greater speed, scale, and efficiency. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251224890815/en/ CES 2026: GIGABYTE is “AI Forward,” Showcasing AI Factory, Physical AI, and Agentic AI Solutions Build Future-Ready AI Factory GIGABYTE introduces its one-stop AI data center solution with GIGAPOD, a modular “Building-Block Design” that integrates high-performance servers, high-speed netw
Cooler Master Launches the MasterFrame 360 Series With Panorama, Stage Mirror and Stage LCD Versions5.1.2026 18:41:00 CET | Press release
Designed for Powerful PC Builds and Personal Expression — A Showcase Without Limits Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced the launch of the MasterFrame 360 Series. This new family of PC cases is designed for creators and enthusiasts who want a powerful PC build and a platform to express their personal style and be their “Showcase Without Limits.” With advanced cooling capacity and a 360-degree display stage, the series offers a blend of performance and presentation. Across the series, the MasterFrame 360 platform gives builders space for up to twelve 120 mm fans or a mix of 120, 140, and 200 mm options. Support for radiators up to 360 mm, plus clearance for flagship GPUs and PSUs, ensures great cooling no matter what you are doing. With compatibility for Mini-ITX, Micro-ATX, ATX, and BTF (back-connect) motherboards, every build remains clean, optimized, and future-ready. “Our community builds PCs that reflect who they are,” said M
Cooler Master Introduces COSMOS Alpha5.1.2026 18:38:00 CET | Press release
A PC Case for Unlimited Layout, Cooling, and Customized Builds Cooler Master, a global leader in PC components and tech lifestyle solutions, today announced COSMOS Alpha, the next evolution of its iconic COSMOS series. The COSMOS Alpha reflects Cooler Master’s commitment to FreeForm 2.0 with its modular, open, and customizable technology. It gives boundary-pushing PC builders the freedom to shape the form and performance of their system. “COSMOS has always represented the height of craftsmanship and customization,” said Matteo Stracciari, General Manager of Cooler Master. “COSMOS Alpha carries that legacy forward in a flagship platform where every detail can be adjusted, optimized, or reimagined to match a builder’s vision.” A Signature Flagship Design COSMOS Alpha preserves the series’ premium modular design with distinctive curved aluminum frames and tempered glass side panels. Under-case ARGB lighting adds a refined visual accent that complements performance builds and showcase syst
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom